US FDA’s Drug Shortage Program On ‘Site Engagement’ To Be Nixed In GDUFA III

Pharmaceutical manufacturing line
Facility inspections remained a discussion topic during GDUFA III negotiations in April. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics